Redox Dual Action

Boswellia's redox behaviour is different from more classical dual-action compounds such as curcumin. Its dominant role is anti-inflammatory, but downstream oxidative stress can still contribute to tumour-cell kill in the right context.

In healthy tissue

• suppresses NF-κB, COX-2, and 5-LOX

• reduces inflammatory damage

• supports normal-tissue resilience during radiotherapy or treatment stress

In tumour cells

• downstream ROS accumulation may occur after PI3K/Akt inhibition and mitochondrial stress

• tumour cells dependent on inflammatory survival signalling may be more vulnerable to this shift

Why 5-LOX matters

One of AKBA's distinctive features is direct 5-lipoxygenase inhibition. That gives Boswellia a unique anti-inflammatory angle compared with several other oncology adjuncts.

Practical interpretation

Boswellia is best understood as primarily anti-inflammatory with a secondary, context-dependent oxidative component in tumour cells.

Jump to another Boswellia page

Core pages

• Boswellia in Oncology Overview

• Evidence Summary

• Anticancer Mechanisms

• Boswellia Evidence by Cancer Type

Mechanism deep dives

• Redox Dual Action

• NRF2 Impact

• Ferroptosis Findings

• Immune Effects

Practical pages

• Pharmacokinetics & Metabolism

• Safety & Interactions

• Synergistic Combinations

• Hydroxychloroquine + Boswellia

• Dosing & Timing

• Sourcing Quality Boswellia

Cancer-type pages

• Glioblastoma & Brain Tumours

• Breast Cancer

• Colorectal Cancer

• Pancreatic Cancer

• Prostate Cancer

• Non-Small Cell Lung Cancer

• Ovarian Cancer

• Other Cancer Types